Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

Grothey, Axel; Sobrero, Alberto; Siena, Salvatore; Falcone, Alfredo; Ychou, Marc; Lenz, Heinz‐Josef; Yoshino, Takayuki; Cihon, Frank; Wagner, Andrea; Van Cutsem, Eric

doi:10.1200/jco.2012.30.4_suppl.lba385

Public

Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

Published in Journal of Clinical Oncology • Feb 1, 2012

Authors:

Axel Grothey

Alberto Sobrero

Salvatore Siena

Abstract

LBA385 Background: Regorafenib (BAY 73-4506) is an oral multikinase inhibitor of a broad range of angiogenic, oncogenic, and stromal kinases. The phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in pts with mCRC who had progressed after all approved standard thera...

Subject

Regorafenib

Medicine

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!